







JOB OFFER								
REFERENCE		OPENING DATE			DEADLINE			
2018.157	018.157 18/03/2022				27/03/2022			
PROFILE REQUIREMENTS								
EXCLUSIVE REQUIREMENTS: (1)								
ACADEMIC DEGREE		PhD						
FORMATION		Psychology + mas	ster					
EXPERIENCE		EXPERIENCE IN MEXPERIENCE IN C						
		VALUED MER						
FURTHER Experience in Alzheimer's disease clinical trials as a rater Coordination of clinical trials								
LANGUAGES	EI	ENGLISH						
CONTRACT INFORMATION								
TYPE OF CONTRA		EXPECTED INCORPORATION DATE		JOB STATUS				
Eventual		April 2022			Completa (35h/semana)			
ANNUAL GROSS SALARY IN FULL TIME			DURATION OF THE CONTRACT					
29.590,87 €			6 months, (extensible depending on the project and financial availability)					
WORK LOCATIONS			UNIT/DEPARTMENT					
University Hospital Marqués de Valdecilla-IDIVAL			Neurology Service					
		OFFER DES	CRIPTIC	ON				
		Research <sup>-</sup>	Technicia	an				
DESCRIPTION OF THE TASKS IN THE PROJECT								
STUDY AND CLINICAL TRIALS COORDINATION. Rater in clinical trials of patients with cognitive impairment. Participation in research projects.								
PRINCIPAL INVESTIGA RESPONSABLE	ATOR /	RESEARCH GRO	UP		RESEARCH PROJECT			
Eloy Rodriguez Rodrigue		NEURODEGENERAT DISORDERS/NEURO			ed, double-blind, placebo- d, parallel-group, multicenter study te the efficacy and safety of gan-			

NCE

randomized,

placebo-

(prodromal to mild) alzheimer's disease"

and the Sub-studies: "longitudinal substudy of pet for amyloid-associated amyloid:

multicenter,

double-blind,

phase

randomized,

iii,









the efficacy and safety of gantenerumab in patients with EARLY (PRODROMIC TO MILD) ALZHEIMER'S DISEASE" and "EXPLORATORY SUB STUDY OF PET FOR TAU ASSOCIATED WITH: A PHASE III, MULTICENTRIC, RANDOMIZED, DOUBLE-BINDED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY to evaluate the efficacy and safety of gantenerumab in patients with early	controlled, parallel-group study to evaluate
ALZHEIMER'S DISEASE" and "EXPLORATORY SUB STUDY OF PET FOR TAU ASSOCIATED WITH: A PHASE III, MULTICENTRIC, RANDOMIZED, DOUBLE-BINDED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY to evaluate the efficacy and safety of gantenerumab in patients with early	the efficacy and safety of gantenerumab in
SUB STUDY OF PET FOR TAU ASSOCIATED WITH: A PHASE III, MULTICENTRIC, RANDOMIZED, DOUBLE-BINDED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY to evaluate the efficacy and safety of gantenerumab in patients with early	patients with EARLY (PRODROMIC TO MILD)
WITH: A PHASE III, MULTICENTRIC, RANDOMIZED, DOUBLE-BINDED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY to evaluate the efficacy and safety of gantenerumab in patients with early	ALZHEIMER'S DISEASE" and "EXPLORATORY
RANDOMIZED, DOUBLE-BINDED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY to evaluate the efficacy and safety of gantenerumab in patients with early	SUB STUDY OF PET FOR TAU ASSOCIATED
CONTROLLED, PARALLEL GROUP STUDY to evaluate the efficacy and safety of gantenerumab in patients with early	WITH: A PHASE III, MULTICENTRIC,
evaluate the efficacy and safety of gantenerumab in patients with early	RANDOMIZED, DOUBLE-BINDED, PLACEBO-
gantenerumab in patients with early	CONTROLLED, PARALLEL GROUP STUDY to
, , , , , , , , , , , , , , , , , , , ,	evaluate the efficacy and safety of
	gantenerumab in patients with early
(prodromal to mild) alzheimer's disease".	(prodromal to mild) alzheimer's disease".

RECRUITMENT INFORMATION					
SELECTION PROCESS STAGES (2)	EMPLOYMENT EXCHANGE				
Preselection: Inverview:maximum candidates to be interviewed: 2 those with the highest score. Tribunal report: Resolution:	NOT				

## **SELECTION BOARD**

- Jon Infante, Project's Main Researcher Galo Peralta, IDIVAL's Management Director
- Patricia Álvarez-Ingelmo, IDIVAL Human Resources Coordinator (She will act as registrar of the selection board).

VALUATION OF MERITS						
MERITS	EVALUATION	SC	MAXIMUM			
Training in Neurosciences	Accreditation	Requirement compliance	Y/N	10		
Experience in Alzheimer's disease clinical trials as a rater	cv	Requirement compliance	Y/N	20		
Coordination of clinical trials	cv	Requirement compliance	Y/N	25		
English level medium-high	cv	Requirement compliance	Y/N	5		
FINAL SCORE						
MAXIMUM TOTAL SO	60					
MAXIMUM TOTAL SO	40					
MAXIMUM TOTAL SO	100					

<sup>(2)</sup> See duration of each phase in the document "Selection Process"









In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at www.idival.org/es/Política-de-Privacidad